Stem cells in colon cancer

Clinical Colorectal Cancer

Volumn 7, Issue 2, 2008, Pages 92-98

  Pohl, Alexandra ^a   Lurje, Georg ^a   Kahn, Michael ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Stem cell niche; Transient amplifying cells; Wnt signaling pathway; Catenin

Indexed keywords

BRAIN CANCER; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CELL RENEWAL; COLON CANCER; HUMAN; LEUKEMIA; LIVER CANCER; MELANOMA; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STEM CELL; TUMOR GROWTH;

EID: 42049117510     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.012     Document Type: Review

References (108)

1. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007; 58:267-84.
2. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004; 51:1-28.
3. Cohnheim J. Ueber Entzuendung und Eiterung [in German]. Path Anat Physiol Klin Med 1867; 40:1-79.
4. Cohnheim J. Congenitales, Quergestreiftes Muskelsarkom der Nireren [in German]. Virchows Arch 1875; 65:64.
5. Zhang M, Rosen JM. Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev 2006; 16:60-4.
6. McDonald SA, Preston SL, Lovell MJ, et al. Mechanisms of disease: from stem cells to colorectal cancer. Nat Clin Pract Gastroenterol Hepatol 2006; 3:267-74.
7. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002; 360:1587-9.
8. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg 2001; 233:322-37.
9. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004; 23:7274-82.
10. Fearon ER. Genetic alterations underlying colorectal tumorigenesis. Cancer Surv 1992; 12:119-36.
11. Brittan M, Wright NA. Stem cell in gastrointestinal structure and neoplastic development. Gut 2004; 53:899-910.
12. Gudjonsson T, Magnusson MK. Stem cell biology and the cellular pathways of carcinogenesis. Apmis 2005; 113:922-9.
13. Baba S. Recent advances in molecular genetics of colorectal cancer. World J Surg 1997; 21:678-87.
14. Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990; 110:1001-20.
15. Wong WM, Wright NA. Cell proliferation in gastrointestinal mucosa. J Clin Pathol 1999; 52:321-33.
16. Hatina J, Schulz WA, Fischer J, et al. Tumour stem cells - a new concept in tumour biology [in German]. Dtsch Med Wochenschr 2007; 132:1629-32.
17. Bonnet D, JE Dick. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-7.
18. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434:843-50.
19. Kelly PN, Dakic A, Adams JM, et al. Tumor growth need not be driven by rare cancer stem cells. Science 2007; 317:337.
20. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432:396-401.
21. Yuan X, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004; 23:9392-400.
22. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65:9328-37.
23. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983-8.
24. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65:10946-51.
25. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132:2542-56.
26. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67:1030-7.
27. Bapat SA, Mali AM, Koppikar CB, et al. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005; 65:3025-9.
28. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445:106-10.
29. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445:111-5.
30. Bruce WR, Van Der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 1963; 199:79-80.
31. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature 2001; 414:98-104.
32. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006; 66:1883-90; discussion 1895-6.
33. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449:1003-7.
34. McClanahan T, Koseoglu S, Smith K, et al. Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol Ther 2006; 5:419-26.
35. Yamamoto Y, Sakamoto, Fujii G, et al. Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology 2003; 37:528-33.
36. Bjerknes M, Cheng H. Clonal analysis of mouse intestinal epithelial progenitors. Gastroenterology 1999; 116:7-14.
37. Gordon JI, Schmidt GH, Roth KA. Studies of intestinal stem cells using normal, chimeric, and transgenic mice. FASEB J 1992; 6:3039-50.
38. Perryman SV, Sylvester KG. Repair and regeneration: opportunities for carcinogenesis from tissue stem cells. J Cell Mol Med 2006; 10:292-308.
39. Leedham SJ, Brittan M, McDonald SA, et al. Intestinal stem cells. J Cell Mol Med 2005; 9:11-24.
40. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105-11.
41. Lemischka IR, Moore KA. Stem cells: interactive niches. Nature 2003; 425:778-9.
42. Austin TW, Solar GP, Ziegler FC, et al. A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells. Blood 1997; 89:3624-35.
43. Spink KE, Polakis P, Weis WI. Structural basis of the Axin-adenomatous polyposis coli interaction. EMBO J 2000; 19:2270-9.
44. Bhardwaj G, Murdoch B, Wu D, et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2001; 2:172-80.
45. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425:841-6.
46. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423:255-60.
47. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425:836-41.
48. Takahashi-Yanaga, F, Sasaguri T. The Wnt/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci 2007; 104:293-302.
49. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411:349-54.
50. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653:1-24.
51. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103:311-20.
52. Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 1993; 2:425-34.
53. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66:589-600.
54. Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991; 253:665-9.
55. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275:1787-90.
56. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5:275-84.
57. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281:1509-12.
58. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999; 96:5522-7.
59. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin Dl in colon carcinoma cells. Nature 1999; 398:422-6.
60. Kim PJ, Plescia J, Clevers H, et al. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003; 362:205-9.
61. Zhang T, Otevrel T, Gao Z, et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer [published erratum in: Cancer Res 2002; 62:7379]. Cancer Res 2001; 61:8664-7.
62. Stein U, Arlt F, Walther W, et al. The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology 2006; 131:1486-500.
63. Gradl D, Kuhl M, Wedlich D. The Wnt/Wg signal transducer beta-catenin controls fibronectin expression. Mol Cell Biol 1999; 19:5576-87.
64. Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423:409-14.
65. Kimelman D, Xu W. Beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene 2006; 25:7482-91.
66. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14:1837-51.
67. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17:45-51.
68. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998; 14:59-88.
69. Zhou BP, Hung MC. Wnt, hedgehog and snail: sister pathways that control by GSK-3beta and beta-Trcp in the regulation of metastasis. Cell Cycle 2005; 4:772-6.
70. Korinek V, Barker N, Moerer P, et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998; 19:379-83.
71. Fevr T, et al. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol 2007; 27:7551-9.
72. Fearon ER, Jones PA. Progressing toward a molecular description of colorectal cancer development. FASEB J 1992; 6:2783-90.
73. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.
74. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005; 307:1904-9.
75. Dalerba P, Dyalla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007; 104:10158-63.
76. Ieta K, Tanaka F, Haraguchi N, et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 2007; 15:638-48.
77. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC 133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95:952-8.
78. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90:5002-12.
79. Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 2000; 97:14720-5.
80. Corbeil D, Röper K, Hellwig A, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000; 275:5512-20.
81. Richardson GD, Robson CN, Lang SN, et al. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117(pt 16):3539-45.
82. Torrente Y, Belicchi M, Sampaolesi M, et al. Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J Clin Invest 2004; 114:182-95.
83. Zhong X, Li Y, Peng F, et al. Identification of tumorigenic retinal stem-like cells in human solid retinoblastomas. Int J Cancer 2007; 121:2125-31.
84. Ferrandina G, Bonanno G, Pierelli L, et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 2007. Epub ahead of print.
85. Suetsugu A, Nagaki M, Aoki H, et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006; 351:820-4.
86. Todaro M, Zerilli M, Ricci-Vitiani L,et al. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res 2006; 66:1491-9.
87. Stassi G, Todaro M, Zerilli M, et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 2003; 63:6784-90.
88. Dancescu M, Rubio-Trujillo M, Biron G, et al. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992; 176:1319-26.
89. Conticello C, Pedini F, Zeuner A, et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol 2004; 172:5467-77.
90. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997; 71:241-319.
91. Weichen W, Knösel T, Bellach J, et al. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004; 57:1160-4.
92. Massard C, Deutsch E, Soria JC. Tumour stem cell-targeted treatment: elimination or differentiation. Arm Oncol 2006; 17:1620-4.
93. Yilmaz OH, Valdez R, Theisen, et al. PTEN dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441:475-82.
94. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004; 101:14228-33.
95. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66:85-94.
96. Budak MT, Alpdogan OS, Zhou M, et al. Ocular surface epithelia contain ABCG2-dependent side population cells exhibiting features associated with stem cells. J Cell Sci 2005; 118(pt 8):1715-24.
97. de Paiva CS, Chen Z, Corrales RM, et al. ABCG2 transporter identifies a population of clonogenic human limbal epithelial cells. Stem Cells 2005; 23:63-73.
98. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7:1028-34.
99. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81:116-24.
100. Miller SJ, Lavker RM, Sun TT. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta 2005; 1756:25-52.
101. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000; 25:1-6.
102. Lepourcelet M, Chen YN, France DS, et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004; 5:91-102.
103. Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67:8014-21.
104. McMillan M, Kahn M. Investigating Wnt signaling: a chemogenomic safari. Drug Discov Today 2005; 10:1467-74.
105. Teo JL, Ma H, Nguyen C, et al. Specific inhibition of CBP/beta-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation. Proc Natl Acad Sci U S A 2005; 102:12171-6.
106. Ma H, Nguyen C, Lee KS, et al. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 2005; 24:3619-31.
107. Emami KH, Nguyen C, Ma H, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [published erratum in: Proc Natl Acad Sci U S A 2004; 101:16707]. Proc Natl Acad Sci U S A 2004; 101:12682-7.
108. Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1:389-402.